Integral Molecular partners with Merus to discover novel therapeutic monoclonal antibodies

(Integral Molecular) Integral Molecular, the industry leader in the discovery of monoclonal antibodies (MAbs) against membrane proteins, and Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets.

from EurekAlert! - Social and Behavioral Science https://ift.tt/2ry8JOi